InvestorsHub Logo
Followers 17
Posts 3850
Boards Moderated 0
Alias Born 01/02/2012

Re: MERCURIAL post# 6383

Thursday, 04/19/2018 3:16:52 PM

Thursday, April 19, 2018 3:16:52 PM

Post# of 11473
Big News for the sector....and EMHTF has lots of CBD related products. I know this is an American bit of news but it should help the whole sector.

IMO GLTA

FDA panel unanimously backs GW Pharma's cannabis-based epilepsy drug

(Reuters) - GW Pharmaceuticals Plc’s cannabis-derived drug to treat a severe form of childhood epilepsy was unanimously backed on Thursday by an advisory panel to the U.S. Food and Drug Administration.

The 13-to-0 vote sets the stage for the approval of the first-ever cannabis-derived treatment in the United States.

The panel’s backing was widely expected, after FDA staff on Tuesday gave a favorable review citing findings from three clinical studies that showed the drug reduced frequency of seizures in patients with the disease when added to a current therapy.

The FDA does not have to act on the recommendations of its experts, but typically does.


A potential approval of the drug, Epidiolex, a final decision on which is due by June 27, would confirm the therapeutic benefits of cannabidiol (CBD) - an active ingredient found in marijuana from which the drug is derived.

Epidiolex is designed to treat Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS), rare childhood-onset forms of epilepsy that are among the most resistant to treatment.

“There is little evidence that CBD has meaningful abuse potential,” an FDA staffer said during the meeting.

https://www.reuters.com/article/us-gw-fda/fda-panel-unanimously-backs-gw-pharmas-cannabis-based-epilepsy-drug-idUSKBN1HQ2CG
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.